Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Texas: - Research Site — Austin, Texas
- Research Site — Dallas, Texas
- Research Site — El Paso, Texas
- Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Sites in Texas: - Texas Oncology - Abilene - Antilley Road /ID# 265820 — Abilene, Texas
- Texas Oncology - Dallas - Worth Street /ID# 265806 — Dallas, Texas
- Baylor Scott and White Research Institute /ID# 260853 — Dallas, Texas
Phase 3 Recruiting Industry
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namode…
Sponsor: Can-Fite BioPharma
NCT ID: NCT05201404
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Texas: - Liver Institute at Methodist Dallas — Dallas, Texas
- Moody Outpatient Center ? Parkland Health — Dallas, Texas
- Texas Oncology (Worth) - USOR — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- Texas Oncology - Denison Cancer Center — Denison, Texas
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- MD Anderson League City — League City, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Texas: - Clinical Trial Network — Houston, Texas
- Oncology and Hematology of South Texas, PA — Laredo, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Texas: - Research Site 135 — Austin, Texas
- Research Site 120 — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…
Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in Texas: - Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas
- DHR Health Institute for Research & Development — Edinburg, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Texas Health Science Center - San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04524871
Sites in Texas: - Parkland Health & Hospital System — Dallas, Texas
- The University of Texas Southwestern Medical Center at Dallas — Dallas, Texas
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Texas: - USA13-0 — Anderson, Texas
- USA12-0 — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Sponsor: RayzeBio, Inc.
NCT ID: NCT06726161
Sites in Texas: - Research Facility — Houston, Texas
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced un…
Sponsor: Replimune, Inc.
NCT ID: NCT05733598
Sites in Texas: - Houston Methodist Hospital Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT05775159
Sites in Texas: - Research Site — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The s…
Sponsor: Iterion Therapeutics
NCT ID: NCT05797805
Sites in Texas: - UT Southwestern — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GP…
Sponsor: AstraZeneca
NCT ID: NCT06795022
Sites in Texas: - Research Site — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 yea…
Sponsor: Eureka Therapeutics Inc.
NCT ID: NCT04864054
Sites in Texas: - University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas
Phase 2 Recruiting Academic/Other
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Sponsor: Allison O'Neill, MD
NCT ID: NCT04134559
Sites in Texas: - Baylor College of Medicine — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HC…
Sponsor: Anwaar Saeed
NCT ID: NCT06698250
Sites in Texas: - Houston Methodist Neal Cancer Center — Houston, Texas
- Mays Cancer Center, UT Health San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophos…
Sponsor: Riboscience, LLC.
NCT ID: NCT07175441
Sites in Texas: - START Dallas Fort Worth — Fort Worth, Texas